Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock
Werte in diesem Artikel
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium also includes the Zacks Style Scores. What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.The Style Scores are broken down into four categories:Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum. How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.#1 (Strong Buy) stocks have produced an unmatched +23.64% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.That's where the Style Scores come in.To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.Stock to Watch: BioMarin Pharmaceutical (BMRN)San Rafael, CA-based BioMarin Pharmaceutical Inc. focuses on the development and commercialization of treatments for life-threatening severe medical conditions, mainly for children.BMRN is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.Additionally, the company could be a top pick for growth investors. BMRN has a Growth Style Score of B, forecasting year-over-year earnings growth of 25.9% for the current fiscal year.12 analysts revised their earnings estimate higher in the last 60 days for fiscal 2025, while the Zacks Consensus Estimate has increased $0.16 to $4.43 per share. BMRN also boasts an average earnings surprise of +25.7%.With a solid Zacks Rank and top-tier Growth and VGM Style Scores, BMRN should be on investors' short list.Research Chief Names "Single Best Pick to Double"From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report BioMarin Pharmaceutical Inc. (BMRN): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks
Übrigens: Biomarin Pharmaceutical und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!
Ausgewählte Hebelprodukte auf Biomarin Pharmaceutical
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Biomarin Pharmaceutical
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Quelle: Zacks
Nachrichten zu Biomarin Pharmaceutical Inc.
Analysen zu Biomarin Pharmaceutical Inc.
Datum | Rating | Analyst | |
---|---|---|---|
14.12.2018 | Biomarin Pharmaceutical Outperform | Wolfe Research | |
01.10.2018 | Biomarin Pharmaceutical Overweight | Cantor Fitzgerald | |
07.08.2018 | Biomarin Pharmaceutical Buy | Stifel, Nicolaus & Co., Inc. | |
03.08.2018 | Biomarin Pharmaceutical Buy | Stifel, Nicolaus & Co., Inc. | |
16.05.2018 | Biomarin Pharmaceutical Buy | Canaccord Adams |
Datum | Rating | Analyst | |
---|---|---|---|
14.12.2018 | Biomarin Pharmaceutical Outperform | Wolfe Research | |
01.10.2018 | Biomarin Pharmaceutical Overweight | Cantor Fitzgerald | |
07.08.2018 | Biomarin Pharmaceutical Buy | Stifel, Nicolaus & Co., Inc. | |
03.08.2018 | Biomarin Pharmaceutical Buy | Stifel, Nicolaus & Co., Inc. | |
16.05.2018 | Biomarin Pharmaceutical Buy | Canaccord Adams |
Datum | Rating | Analyst | |
---|---|---|---|
15.09.2017 | Biomarin Pharmaceutical Sector Perform | RBC Capital Markets | |
30.03.2017 | Biomarin Pharmaceutical Neutral | UBS AG | |
02.03.2017 | Biomarin Pharmaceutical Neutral | Instinet | |
29.02.2016 | Biomarin Pharmaceutical Neutral | Wedbush Morgan Securities Inc. | |
25.11.2015 | Biomarin Pharmaceutical Perform | Oppenheimer & Co. Inc. |
Datum | Rating | Analyst | |
---|---|---|---|
Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar. Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Biomarin Pharmaceutical Inc. nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen